Insights

What’s with the Immutep (ASX:IMM) share price today?

The Immutep (ASX: IMM) share price has failed to fire up this morning, after releasing an announcement on its continued clinical studies.
The post What’s with the Immutep (ASX:IMM) share price today? appeared first on The Motley Fool Australia. –

Man thinking and scratching his beard as if asking whether the altium share price is a good buy

The Immutep Ltd (ASX: IMM) share price has failed to rally this morning after the company released an update on its cancer trial.

The Sydney based biotechnology company’s share price lifted 1.23% to 41 cents in early morning trade, but has since retreated back to its opening price of 40 cents.

What did Immutep announce?

Immutep reported it has enrolled and dosed its last patient for stage 2 Part C of its TACTI-002 Phase II study. This marks the completion of recruitment for the important trial.

Immutep is evaluating its lead product candidate, eftilagimod alpha (“efti”), in combination with MSD’s KEYTRUDA (pembrolizuman). In Part C, the study focuses on treating patients with second-line head and neck squamous cell carcinoma (HNSCC).

This comes after the company announced in December that the United States Patent & Trade Mark Office had granted its patent, entitled Combined Preparations for the Treatment of Cancer or Infection.

Importantly, Immutep believes the new patent covers the combination of ingredients used in the TACTI-002 Phase II study.

Interim data

Immutep reported that interim data from the TACTI-002 study was encouraging. Subsequently, while at the Society for Immunotherapy of Cancer, the company mentioned the second line HNSCC patient data was very robust and formed a basis for additional clinical development.

Lastly, Immutep notified the market that the TACTI-002 trial involving patients with first-line non-small cell lung cancer (NSCLC) had commenced. An additional 4 new patients have also been recruited, on top of the already 74 patients that were previously announced on 19 November. 40 of the 110 patients with first-line NSCLC have now been recruited for Part A of the TACTI-002 study.

The company expects further interim data from the TACTI-002 study in the first half of 2021.

About the Immutep share price

Immutep shares have been rallying for the last 12 months, with a 1-year return of 52.83% compared to the S&P/ASX 200 Index (ASX: XJO) loss of 1.85% over the same period.

The company has now grown to a $262.73 million market capitalisation.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

More reading

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post What’s with the Immutep (ASX:IMM) share price today? appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!